Longeveron LGVN
NASDAQ LGVN
$0.84 +0.02 (+2.02%)
At close: Aug 21, 2026 · 4:00 PM EDT

Longeveron (LGVN) Other Non-Current Assets (2021 - 2026)

Longeveron (LGVN) posted quarterly Other Non-Current Assets of $18000.0 for Q1 2026, down 91.04% year-over-year from $201000.0 in Q1 2025, and down 89.77% quarter-over-quarter from $176000.0 in Q4 2025.

Longeveron (LGVN) Other Non-Current Assets (2021 - 2026) Analysis & Trends

Longeveron's Other Non-Current Assets history runs 6 years deep, the most recent figure standing at $18000.0 for Q1 2026.

  • In Q1 2026, Other Non-Current Assets fell 91.04% year-over-year to $18000.0; the TTM figure through Mar 2026 stood at $18000.0 (down 91.04% YoY), while the FY2025 annual figure was $176000.0, down 12.87% from the prior year.
  • Other Non-Current Assets for Q1 2026 stood at $18000.0, down from $176000.0 in the prior quarter.
  • The five-year high for Other Non-Current Assets was $247000.0 in Q1 2023, with the low at $18000.0 in Q1 2026.
  • The 5-year median for Other Non-Current Assets is $200500.0 (2025), against an average of $191142.9.
  • The sharpest annual moves came in 2022 and 2026: Other Non-Current Assets soared 37.85% in 2022, then slumped 91.04% in 2026.
  • Longeveron's Other Non-Current Assets stood at $244000.0 in 2022, then declined by 20.9% to $193000.0 in 2023, then increased by 4.66% to $202000.0 in 2024, then declined by 12.87% to $176000.0 in 2025, then plunged by 89.77% to $18000.0 in 2026.
  • Business Quant data shows LGVN's Other Non-Current Assets at $18000.0 in Q1 2026, $176000.0 in Q4 2025, and $178000.0 in Q3 2025.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Other Non-Current Assets (Qtr)
1 Vertex Pharmaceuticals 139.13 Bn 131.28 Bn 2.84 Bn 1.25 Bn
2 Regeneron Pharmaceuticals 85.77 Bn 77.77 Bn 3.93 Bn 2.31 Bn
3 Argenx Se 64.64 Bn 59.46 Bn 1.37 Bn 124.00 Mn
4 Moderna 58.29 Bn 53.16 Bn 52.00 Mn 618.00 Mn
5 BeOne Medicines 41.92 Bn 36.82 Bn 1.53 Bn 109.58 Mn
6 Alnylam Pharmaceuticals 31.58 Bn 28.28 Bn 992.69 Mn 65.13 Mn
7 BioNTech SE 28.12 Bn 9.73 Bn 668.28 Mn 202.31 Mn
8 Insmed 27.39 Bn 26.22 Bn 358.27 Mn 104.44 Mn
9 Royalty Pharma 27.27 Bn 26.43 Bn - 62.96 Mn
10 Longeveron 26.51 Mn 16.41 Mn 182,000.00 12,000.00

Historic Data

Download Data
DateValue
Jun 30, 2026 12,000.00
Mar 31, 2026 18,000.00
Dec 31, 2025 176,000.00
Sep 30, 2025 178,000.00
Jun 30, 2025 200,000.00
Mar 31, 2025 201,000.00
Dec 31, 2024 202,000.00
Sep 30, 2024 203,000.00
Jun 30, 2024 204,000.00
Mar 31, 2024 190,000.00
Dec 31, 2023 193,000.00
Sep 30, 2023 197,000.00
Jun 30, 2023 223,000.00
Mar 31, 2023 247,000.00
Dec 31, 2022 244,000.00
Dec 31, 2021 177,000.00